Stifel Nicolaus Initiates Momenta Pharmaceuticals At Buy

Stifel Nicolaus initiated coverage on

with a Buy rating. The target price for Momenta Pharmaceuticals is set to $26. Momenta Pharmaceuticals shares have gained 63.96 percent over the past 52 weeks, while the S&P 500 index has surged 9.66 percent in the same period. Momenta Pharmaceuticals' shares climbed 1.38 percent to close at $21.38 yesterday.